Prostate Test Articles & Analysis
29 news found
Metabolomic studies have led to discoveries on a better mechanistic understanding of prostate tumors. Researchers can now assess metabolic fluxes rather than relying on the static snapshot of a traditional blood test. ...
High demand seen for effective disease management platform for second most common cancer in Singaporean men NEW YORK and SINGAPORE, March 28, 2022 /PRNewswire/ -- miR Scientific, a New York-based healthcare company dedicated to transforming global cancer management, and Leonie Hill Capital, a Singapore-based organization focused on large-scale, sophisticated healthcare access and distribution, ...
Through APCaRI, the Lewis team established a patient data registry and biorepository that has grown into one of the largest prostate cancer databases in the world. Dr. Lewis also founded several spinoff companies including Entos Pharmaceuticals, OncoSenX, and Nanostics to bring innovative therapies and diagnostic tests to patients. Nanostics is currently in the ...
The peer-reviewed article published in the journal Frontiers in Oncology (article), shows that the prostate cancer test based on CTC harvested with the ISET® technology and identified by the Immuno-Cytochemistry (ICC) PSA marker has an estimated positive-predictive-value (PPV) of 99% and negative-predictive-value (NPV) of 97%, providing a more reliable ...
NEW YORK and SAN JUAN, Puerto Rico, Aug. 18, 2022 /PRNewswire/ -- miR Scientific, LLC announced the launch of national event #CanDoBlue to create awareness of the need for widespread prostate cancer testing during the 2022 Prostate Cancer Awareness Month (also known as "PCAM"). ...
NEW YORK, July 13, 2022 /PRNewswire/ -- miR Scientific, LLC announces the miR Sentinel™ Prostate Cancer Test is now commercially available in the United States, Puerto Rico and select international markets. ...
IRVINE, CA, and HERSTAL, BELGIUM – May 19, 2022 – – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial stage precision diagnostics company, announces that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies under its MolDX program, has finalized a foundational Local Coverage Determination (LCD) for Molecular Biomarkers to ...
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer Early Detection (version ...
In addition to the 55 percent reduction in biopsy recommendations subsequent to the test, IsoPSA also demonstrated both confirmatory and discriminatory power, most notably that providers changed their pre-test ‘biopsy’ recommendations to ‘no biopsy’ recommendations in 90 percent of the cases following receipt of patient IsoPSA results ...
The test integrates genomic and epigenomic signatures to detect disease without the need for tumor tissue. ...
CT About the Oncotype DX and Oncotype MAP™ Portfolio of Tests The Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumour in order to optimise cancer treatment decisions. In breast cancer, the Oncotype DX Breast Recurrence Score test is the ...
RxPONDER is an independently conducted trial of a very large number of women with involved lymph nodes who were tested using the Oncotype DX test. The results show that the test can distinguish a majority of postmenopausal women who can safely avoid chemotherapy. ...
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Data presented from a cross-validation study at the American Urological Association's (AUA) 2021 Annual Meeting confirms that the miR Sentinel® Prostate Cancer Test can detect and risk-classify prostate cancer at the molecular level with predictive accuracy of over 90%, based on a single urine sample. ...
In the first presentation, entitled “IsoPSA: Clinical Performance of a Single Parameter, Structure Based Test for High Grade Prostate Cancer in a Large, Multicenter, Prospective Validation Trial”, Dr. ...
miR Scientific's award-winning miR Sentinel® Prostate Test is a standalone, non-invasive liquid biopsy urine test that can, from a single urine specimen, accurately detect molecular evidence of prostate cancer and then classify the severity, or the risk grade, of the malignancy. ...
The second place went to the Turin-based start-up NIB Biotech, that has developed the first rapid urine test for the screening of prostate cancer, capable of contemporary identifying the presence and aggressiveness of a possible case of cancer, helping doctors determine whether a prostate biopsy is necessary. "A rapid ...
Salman will discuss the planned commercial launch of miR Scientific's first product, the miR Sentinel™ Prostate Test. The award-winning, highly accurate liquid biopsy urine test was recently designated Breakthrough Designation status by the Food and Drug Administration, and is expected to be launched commercially later this year. ...
About the Oncotype DX and Oncotype MAP Portfolio of Tests The Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumour in order to optimise cancer treatment decisions. In breast cancer, the Oncotype DX Breast Recurrence Score test is the only ...
Exosome Diagnostics is the world leader in developing exosomal liquid biopsy-based diagnostic assays. The EPI test is a non-invasive, urine-based genomic test that helps inform the prostate biopsy decision. ...
OncoDiag continues to work on the validation of two new diagnostic tests: Prostadiag for the detection of localized prostate cancer and Colodiag for the detection of colorectal cancer. ...
ByOncoDiag